RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for human and animal health, has partnered with Lonza to scale manufacturing of its Purified Exosome Product for chronic wound care and tissue regeneration. The collaboration will support cGMP production of the drug substance for late-phase clinical trials and future commercial supply, enabling the company to bring its therapies to patients more efficiently.

The partnership combines RION’s proprietary biomanufacturing platform with Lonza’s global capabilities in extracellular vesicle development and production. RION’s platform allows the company to produce exosomes with immunomodulatory, anti-inflammatory, and tissue-regenerative properties at scale. Lonza will manufacture the drug substance at its Houston facility, providing technical support to operationalize RION’s processes while maintaining the quality, reproducibility, and traceability required for advanced therapies.

Atta Behfar, cofounder and CEO of RION, said the collaboration “ensures that our proprietary exosome manufacturing platform can be scaled to meet clinical and future commercial demand.” He added that pairing RION’s biomanufacturing expertise with Lonza’s infrastructure “allows us to bring this biologics-based innovation to patients rapidly and reliably, while staying true to our mission of affordable access.”

The Purified Exosome Product is formulated as a shelf-stable lyophilized powder, allowing multiple routes of administration and broad applicability across indications. RION is advancing clinical programs in tissue regeneration, immune-mediated dermatology diseases, musculoskeletal conditions, pulmonary disease, cardiovascular health, and women’s health. The company’s platform is designed to accelerate access to transformative regenerative therapies while maintaining high standards of safety and quality.

Davide Zocco, commercial development head for exosomes and mRNA technologies at Lonza, added: “Through our collaboration with RION, we will apply our expertise to support the manufacture of the drug substance, aiming to help accelerate the availability of innovative treatments to patients worldwide.” He emphasised that Lonza’s role extends beyond manufacturing, providing technical and regulatory support to ensure the therapies meet clinical and commercial requirements.

This partnership reflects a growing trend of CDMOs supporting the commercialization of next-generation biologics and exosome-based therapies, offering developers both technical know-how and scalable manufacturing solutions. By combining RION’s innovation in regenerative medicine with Lonza’s world-leading capabilities, the collaboration aims to streamline the path from clinical research to patient access globally.